Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial-Rationale and design

Journal of Cardiology

Volumn 62, Issue 1, 2013, Pages 31-36

  Sakata, Yasuhiko ^a   Nochioka, Kotaro ^a   Miura, Masanobu ^a   Takada, Tsuyoshi ^a   Tadaki, Soichiro ^a   Miyata, Satoshi ^a   Shiba, Nobuyuki ^b   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Angiotensin receptor blocker; Heart failure; Hypertension; Olmesartan

Indexed keywords

OLMESARTAN;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN RECEPTOR BLOCKER; HEART FAILURE; HYPERTENSION; OLMESARTAN;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; HYPERTENSION; IMIDAZOLES; PROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME;

EID: 84880035893     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.02.011     Document Type: Article

References (32)

1. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., Oates J.A., Rahko P.S., Silver M.A., Stevenson L.W., Yancy C.W. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391-e479.
2. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., Falk V., Filippatos G., Fonseca C., Gomez-Sanchez M.A., Jaarsma T., Køber L., Lip G.Y., Maggioni A.P., Parkhomenko A., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869.
3. Granger C.B., McMurray J.J., Yusuf S., Held P., Michelson E.L., Olofsson B., Ostergren J., Pfeffer M.A., Swedberg K., CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
4. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675. Valsartan Heart Failure Trial Investigators.
5. Dimopoulos K., Salukhe T.V., Coats A.J., Mayet J., Piepoli M., Francis D.P. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a β-blocker). Int J Cardiol 2004, 93:105-111.
6. McMurray J.J., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., Olofsson B., Yusuf S., Pfeffer M.A., CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
7. Smith D.H., Dubiel R., Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005, 5:41-50.
8. Ichikawa S., Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res 2001, 24:641-646.
9. Tsutamoto T., Nishiyama K., Yamaji M., Kawahara C., Fujii M., Yamamoto T., Horie M. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res 2010, 33:118-122.
10. Sezai A., Soma M., Hata M., Yoshitake I., Unosawa S., Wakui S., Shiono M. Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery-investigation using a candesartan change-over study. Ann Thorac Cardiovasc Surg 2011, 17:487-493.
11. Agata J., Ura N., Yoshida H., Shinshi Y., Sasaki H., Hyakkoku M., Taniguchi S., Shimamoto K. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006, 29:865-874.
12. Zou Y., Akazawa H., Qin Y., Sano M., Takano H., Minamino T., Makita N., Iwanaga K., Zhu W., Kudoh S., Toko H., Tamura K., Kihara M., Nagai T., Fukamizu A., et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004, 6:499-506.
13. Miura S., Fujino M., Hanzawa H., Kiya Y., Imaizumi S., Matsuo Y., Tomita S., Uehara Y., Karnik S.S., Yanagisawa H., Koike H., Komuro I., Saku K. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006, 281:19288-19295.
14. Shiba N., Nochioka K., Kohno H., Matsuki M., Takahashi J., Tada T., Kagaya Y., Shimokawa H. Emerging problems of heart failure practice in Japanese women: lessons from the CHART study. Circ J 2008, 72:2009-2014.
15. Nochioka K., Shiba N., Kohno H., Miura M., Shimokawa H. Both high and low body mass indexes are prognostic risks in Japanese patients with chronic heart failure: implications from the CHART study. J Card Fail 2010, 16:880-887.
16. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., Jones D.W., Materson B.J., Oparil S., Wright J.T., Roccella E.J. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
17. Matsuzawa Y., Funahashi T., Kihara S., Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004, 24:29-33.
18. Chen S.J., Yen C.H., Huang Y.C., Lee B.J., Hsia S., Lin P.T. Relationships between inflammation, adiponectin, and oxidative stress in metabolic syndrome. PLoS One 2012, 7:e45693.
19. Matsubara T., Naruse K., Arakawa T., Nakao M., Yokoi K., Oguri M., Marui N., Amano T., Ichimiya S., Ohashi T., Imai K., Sakai S., Sugiyama S., Ishii H., Murohara T. Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: the PREMIUM Study. J Cardiol 2012, 60:389-394.
20. Sakaguchi M., Fukuda S., Shimada K., Izumi Y., Izumiya Y., Nakamura Y., Nakanishi K., Otsuka K., Ogawa H., Fujita M., Yoshikawa J., Yoshiyama M. Preliminary observations of passive exercise using whole body periodic acceleration on coronary microcirculation and glucose tolerance in patients with type 2 diabetes. J Cardiol 2012, 60:283-287.
21. Ge Q., Gérard J., Noël L., Scroyen I., Brichard S.M. MicroRNAs regulated by adiponectin as novel targets for controlling adipose tissue inflammation. Endocrinology 2012, 153:5285-5296.
22. Karolina D.S., Tavintharan S., Armugam A., Sepramaniam S., Pek S.L., Wong M.T., Lim S.C., Sum C.F., Jeyaseelan K. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab 2012, 97:E2271-E2276.
23. Shiba N., Nochioka K., Miura M., Kohno H., Shimokawa H., CHART-2 Investigators Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan. First report from the CHART-2 study. Circ J 2011, 75:823-833.
24. Miura M., Shiba N., Nochioka K., Takada T., Takahashi J., Kohno H., Shimokawa H., CHART-2 Investigators Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study. Eur J Heart Fail 2012, 14:367-376.
25. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARM-Preserved trial. Lancet 2003, 362:777-781.
26. Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., Anderson S., Donovan M., Iverson E., Staiger C., Ptaszynska A., I-PRESERVE Investigators Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456-2467.
27. Lund L.H., Benson L., Dahlström U., Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 2012, 308:2108-2117.
28. Anand I.S., Rector T.S., Cleland J.G., Kuskowski M., McKelvie R.S., Persson H., McMurray J.J., Zile M.R., Komajda M., Massie B.M., Carson P.E. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 2011, 4:569-577.
29. Yasuda N., Miura S., Akazawa H., Tanaka T., Qin Y., Kiya Y., Imaizumi S., Fujino M., Ito K., Zou Y., Fukuhara S., Kunimoto S., Fukuzaki K., Sato T., Ge J., et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep 2008, 9:179-186.
30. Ogihara T., Nakao K., Fukui T., Fukiyama K., Ueshima K., Oba K., Sato T., Saruta T., Candesartan Antihypertensive Survival Evaluation in Japan Trial Group Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008, 5:393-398.
31. Kasanuki H., Hagiwara N., Hosoda S., Sumiyoshi T., Honda T., Haze K., Nagashima M., Yamaguchi J., Origasa H., Urashima M., Ogawa H., HIJ-CREATE Investigators Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009, 30:1203-1212.
32. Muramatsu T., Matsushita K., Yamashita K., Kondo T., Maeda K., Shintani S., Ichimiya S., Ohno M., Sone T., Ikeda N., Watarai M., Murohara T., NAGOYA HEART Study Investigators Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension 2012, 59:580-586.